A month after Facebook’s botched initial public offering, Wall Street analysts released more than a dozen highly anticipated reports detailing what they think of the company’s potential. For one analyst, the answer is a “money-making opportunity.”
Despite the flurry of debate surrounding ObamaCare, which the U.S. Supreme Court is set to rule on later this week, two managing directors emphasized the new products that will be emerging from pharmaceutical companies’ pipelines soon.
One day after the market’s second-worst session of the year, two portfolio managers shared their best ideas for finding value in a volatile market with CNBC's “Squawk Box.”
Despite news that Chesapeake Energy has named a new chairman and four other independent directors, one analyst told CNBC that the company’s current guidance is looking “less and less plausible every day.”